Aquaculture biotech group Benchmark is starting 2020 with a loss of £2.1 million (€2.4 million/$2.7 million) in earnings before interest, tax, depreciation, and amortization (EBITDA) for the first quarter, compared to the £2.3 million (€2.6 million/$2.9 million) it made in profit during the same period the year prior.
The group was hit by "continuing market weakness" in the advanced nutrition segment, particularly weak shrimp and seabass and seabream markets, coupled with an oversupply in global artemia. Revenues in this segment fell by 28 percent year on year to £11.4
